Lyell Immunopharma, Inc. (NASDAQ:LYEL) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Shares of Lyell Immunopharma, Inc. (NASDAQ:LYEL) have received a consensus recommendation of “Moderate Buy” from the six analysts that are covering the company, MarketBeat Ratings reports. Two analysts have rated the stock with a sell recommendation, three have given a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year target price among analysts that have updated their coverage on the stock in the last year is $43.00.

Several research analysts recently issued reports on LYEL shares. Zacks Research downgraded Lyell Immunopharma from a “hold” rating to a “strong sell” rating in a research report on Tuesday, April 7th. Wall Street Zen downgraded Lyell Immunopharma from a “hold” rating to a “sell” rating in a research report on Saturday. Citizens Jmp started coverage on Lyell Immunopharma in a research report on Monday, March 9th. They set a “market outperform” rating and a $34.00 price objective for the company. Weiss Ratings restated a “sell (d-)” rating on shares of Lyell Immunopharma in a research report on Tuesday, April 21st. Finally, Needham & Company LLC started coverage on Lyell Immunopharma in a research report on Friday, April 10th. They set a “buy” rating and a $44.00 price objective for the company.

Lyell Immunopharma Stock Down 0.5%

Lyell Immunopharma stock opened at $20.72 on Tuesday. The firm has a market capitalization of $483.40 million, a PE ratio of -1.27 and a beta of -0.05. Lyell Immunopharma has a 52 week low of $7.65 and a 52 week high of $45.00. The firm’s 50-day simple moving average is $22.30 and its 200 day simple moving average is $23.45.

Lyell Immunopharma (NASDAQ:LYEL) last posted its earnings results on Thursday, March 12th. The company reported ($7.68) earnings per share for the quarter, missing the consensus estimate of ($2.15) by ($5.53). The business had revenue of $0.01 million for the quarter, compared to analysts’ expectations of $0.02 million. Lyell Immunopharma had a negative net margin of 762,355.56% and a negative return on equity of 90.52%. On average, research analysts expect that Lyell Immunopharma will post -10.45 EPS for the current fiscal year.

Insider Buying and Selling

In related news, insider Gary K. Lee sold 1,671 shares of Lyell Immunopharma stock in a transaction that occurred on Wednesday, February 11th. The stock was sold at an average price of $23.39, for a total transaction of $39,084.69. Following the completion of the transaction, the insider directly owned 16,938 shares in the company, valued at $396,179.82. The trade was a 8.98% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Lynn Seely sold 7,455 shares of Lyell Immunopharma stock in a transaction that occurred on Wednesday, February 11th. The stock was sold at an average price of $23.39, for a total value of $174,372.45. Following the transaction, the chief executive officer owned 74,266 shares of the company’s stock, valued at $1,737,081.74. This represents a 9.12% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 11,310 shares of company stock worth $264,285 in the last ninety days. Insiders own 6.20% of the company’s stock.

Institutional Trading of Lyell Immunopharma

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Invesco Ltd. purchased a new stake in Lyell Immunopharma in the 4th quarter worth approximately $3,036,000. MWG Caph Ltd purchased a new stake in Lyell Immunopharma in the 4th quarter worth approximately $31,030,000. ExodusPoint Capital Management LP purchased a new stake in Lyell Immunopharma in the 4th quarter worth approximately $262,000. Barclays PLC grew its stake in Lyell Immunopharma by 1,239.5% in the 4th quarter. Barclays PLC now owns 15,967 shares of the company’s stock worth $491,000 after acquiring an additional 14,775 shares during the period. Finally, Marshall Wace LLP purchased a new stake in Lyell Immunopharma in the 4th quarter worth approximately $2,257,000. 66.05% of the stock is owned by hedge funds and other institutional investors.

Lyell Immunopharma Company Profile

Lyell Immunopharma is a clinical-stage biotechnology company focused on developing next-generation T cell therapies for cancer. Leveraging a proprietary platform that combines cell therapy, gene editing and molecular discovery, Lyell seeks to overcome key barriers in the treatment of solid tumors. The company’s approach centers on engineering T cells to enhance their persistence, functionality and resistance to the immunosuppressive tumor microenvironment.

The company’s pipeline includes multiple autologous T cell programs engineered to target tumor-associated antigens in solid malignancies such as melanoma, ovarian and pancreatic cancers.